Oculis Holding AG

OCS

Company Profile

  • Business description

    Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

  • Contact

    Bahnhofstrasse 20
    Zug6300
    CHE

    T: +41 417119325

    https://www.oculis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    49

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,900.0321.570.27%
DAX 4024,465.9683.60-0.34%
Dow JONES (US)44,714.68256.380.58%
FTSE 1008,975.60108.581.22%
HKSE24,028.37136.050.57%
NASDAQ20,579.8031.53-0.15%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,274.4711.210.18%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers